Benign Prostatic Hyperplasia
Conditions
Interventions
Intake of L-citruline for 8weeks
Intake of placebo for 8weeks
Sponsors
Nagoya City University Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Subject aged from 45 to 75 years 2.Subject taking PDE5 inhibitor for 4weeks to treat Benign Prostatic Hyperplasia. 3.Subject classified IIEF score 8 to 25 4.Subject having sexual intercourse at least once a 8 week.
Exclusion criteria
Exclusion criteria: 1.Subject receiving a medical treatment for serious renal, hepatic, cardio-vascular, respiratory, endocrine or metabolic disorders 2.Subject having a neurological disease 3.Subject having penile organic dysfunction 4.Subject having endocrine disease 5.Subject injecting insulin 6.Subject receiving hormone replacement therapy 7.Subject diagnosed psychogenic ED 8.Subject having the habit of taking a L-citrulline 9.Subject judged to be ineligible by the investigator for other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erectile function (IIEF,EHS) | — |
Secondary
| Measure | Time frame |
|---|---|
| IPSS,OABSS,frequency volume chart,UFM,residual urine,SEP2, SEP3, GAQ,VAS,blood biochemistry | — |
Countries
Japan
Contacts
Public ContactKazunori Kimura
Graduate School of Medical Sciences, Nagoya City University Department of Clinical Pharmacy
Outcome results
None listed